These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 25311380

  • 21. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R.
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [Abstract] [Full Text] [Related]

  • 22. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE, Birkeland KI.
    Am J Cardiovasc Drugs; 2007 Dec; 7(5):319-35. PubMed ID: 17953471
    [Abstract] [Full Text] [Related]

  • 23. Peroxisome proliferator-activated receptor delta +294T > C polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
    Miao L, Yin RX, Wu DF, Cao XL, Li Q, Hu XJ, Yan TT, Aung LH, Yang DZ, Lin WX.
    Lipids Health Dis; 2010 Dec 21; 9():145. PubMed ID: 21176135
    [Abstract] [Full Text] [Related]

  • 24. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H, Bu P, Xie YH, Luo J, Lei MX, Mo ZH, Liao EY.
    Chin Med J (Engl); 2011 Jan 21; 124(2):172-6. PubMed ID: 21362360
    [Abstract] [Full Text] [Related]

  • 25. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI, Lindström T, Eson Jennersjö P, Paulsson JF, Westermark GT, Olsson AG, Arnqvist HJ.
    Acta Diabetol; 2009 Mar 21; 46(1):35-42. PubMed ID: 18777156
    [Abstract] [Full Text] [Related]

  • 26. Minor alleles of FTO rs9939609 and rs17817449 polymorphisms confer a higher risk of type 2 diabetes mellitus and dyslipidemia, but not coronary artery disease in a Chinese Han population.
    Zhang Y, Chen L, Zhu J, Liu H, Xu L, Wu Y, He C, Song Y.
    Front Endocrinol (Lausanne); 2023 Mar 21; 14():1249070. PubMed ID: 38161971
    [Abstract] [Full Text] [Related]

  • 27. Repaglinide in combination therapy.
    Moses R.
    Diabetes Nutr Metab; 2002 Dec 21; 15(6 Suppl):33-8. PubMed ID: 12702006
    [Abstract] [Full Text] [Related]

  • 28. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF, Van Acker KL, De Leeuw IH.
    Diabetes Res Clin Pract; 2001 Sep 21; 53(3):141-8. PubMed ID: 11483229
    [Abstract] [Full Text] [Related]

  • 29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Sep 21; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 30. Protective role of +294 T/C (rs2016520) polymorphism of PPARD in Mexican patients with colorectal cancer.
    Rosales-Reynoso MA, Wence-Chavez LI, Arredondo-Valdez AR, Dumois-Petersen S, Barros-Núñez P, Gallegos-Arreola MP, Flores-Martínez SE, Sánchez-Corona J.
    Genet Mol Res; 2017 Jan 23; 16(1):. PubMed ID: 28128413
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR.
    Diabet Med; 1998 Jan 23; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [Abstract] [Full Text] [Related]

  • 34. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.
    Wang LC, Fang FS, Gong YP, Yang G, Li CL.
    Medicine (Baltimore); 2018 Sep 23; 97(38):e12476. PubMed ID: 30235745
    [Abstract] [Full Text] [Related]

  • 35. Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.
    Zhou F, Huang Q, Dai X, Yin J, Wu J, Zhou H, Gong Z, Liu Z.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct 23; 36(10):949-57. PubMed ID: 22086013
    [Abstract] [Full Text] [Related]

  • 36. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
    Pei Q, Liu JY, Yin JY, Yang GP, Liu SK, Zheng Y, Xie P, Guo CX, Luo M, Zhou HH, Li X, Liu ZQ.
    Eur J Clin Pharmacol; 2018 Aug 23; 74(8):1021-1028. PubMed ID: 29748863
    [Abstract] [Full Text] [Related]

  • 37. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.
    Yu W, Hu C, Zhang R, Wang C, Qin W, Lu J, Jiang F, Tang S, Bao Y, Xiang K, Jia W.
    Clin Pharmacol Ther; 2011 Mar 23; 89(3):437-42. PubMed ID: 21289621
    [Abstract] [Full Text] [Related]

  • 38. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE.
    Ned Tijdschr Geneeskd; 2001 Aug 11; 145(32):1547-50. PubMed ID: 11525087
    [Abstract] [Full Text] [Related]

  • 39. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects.
    Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K.
    Diabet Med; 2006 Dec 11; 23(12):1307-12. PubMed ID: 17116180
    [Abstract] [Full Text] [Related]

  • 40. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May 22; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.